ClinicalTrials.Veeva

Menu
A

Asheville Clinical Research | Asheville, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

VRDN-003
Teplizumab
Maridebart Cafraglutide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 7 total trials

A Study to Evaluate Solriktug in Adult Participants With Asthma (RAINIER)

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.

Enrolling
Asthma
Biological: NSI-8226
Biological: Placebo

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment.The purpose of this study is to meas...

Enrolling
Type 1 Diabetes Mellitus
Other: Placebo
Drug: Teplizumab

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid E...

Active, not recruiting
Thyroid Eye Disease
Drug: VRDN-003
Drug: Placebo

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid...

Active, not recruiting
Thyroid Eye Disease
Drug: Placebo
Drug: VRDN-003

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Active, not recruiting
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Drug: Maridebart cafraglutide
Drug: Placebo

The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in...

Active, not recruiting
Diabetes Mellitus, Type 1
Drug: Lispro
Drug: HDV-Lispro

Trial sponsors

V
Amgen logo
D
Moderna logo
Sanofi logo
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems